The pharmaceutical industry is using models for treatment adoption that can be traced back over a hundred years. At DeltaMV, we question how relevant these models are in today’s digital world. Should we be looking over the fence at FMCG models and move on from the established approach?   

In this episode, we share key insights from our conversations with clinicians across Asia-Pacific around how they adopt new treatments.